Platelet degranulation and glycoprotein IIbIIIa opening are not related to bleeding phenotype in severe haemophilia A patients

Summary

Recently we reported data suggesting that platelets could compensate for the bleeding phenotype in severe haemophilia A (HA). The aim of this study was to confirm these results in a larger population with a detailed characterisation of clinical phenotype. Patients with diagnostic severe HA (FVIII:C <1%) were scored for clinical phenotype by integrating data on age at first joint bleed, joint damage, bleeding frequency and FVIII consumption. Phenotype was defined as onset of joint bleeding-score + arthropathy-score + joint bleeding-score + (2* treatment intensity-score). After a washout period of three days, blood was collected for measurement of basal level of platelet activation, platelet reactivity, endothelial cell activation and presence of procoagulant phospholipids in plasma. Thirty-three patients with severe HA were included, 13 patients with a mild, 12 patients with an average and eight patients with a severe clinical phenotype. No relevant differences in basal level of platelet activation, platelet reactivity, endothelial cell activation and procoagulant phospholipids between all three groups were observed. The mean annual FVIII consumption per kg did not correlate with the platelet P-selectin expression and glycoprotein (GP)IIbIIIa activation on platelets. In conclusion, variability in clinical phenotype in patients with diagnostic severe HA is not related to platelet activation or reactivity, measured as platelet degranulation and platelet GPIIbIIIa opening.

Keywords

Haemophilia A - clinical phenotype - platelet reactivity - P-selectin - GPIIbIIIa

• References

• 1 Van Dijk K, Fischer K, Va der Bom JG. et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11: 438-443.
• 2 den Uijl IEM, Fischer K, Van Der Bom JG. et al. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia 2009; 15: 83-90.
• 3 White GC, Rosendaal F, Aledort LM, Definitions in haemophilia. et al. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
• 4 Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24: 539-551.
• 5 Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs . The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
• 6 Molho P, Rolland N, Lebrun T. et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia 2000; 06: 23-32.
• 7 van Dijk K, van der Bom JG, Fischer K. et al. Phenotype of severe haemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost 2007; 05: 1062-1064.
• 8 van Dijk K, van der Bom JG, Lenting PJ. et al. Factor VIII half-life and clinical phenotype of severe haemophilia A. Haematologica 2005; 90: 494-498.
• 9 van Bladel ER, Roest M, de Groot PG. et al. Up-regulation of platelet activation in haemophilia A. Haematologica 2011; 96: 888-895.
• 10 Schulman S, Eelde A, Holmstrom M. et al. Validation of a composite score for clinical severity of haemophilia. J Thromb Haemost 2008; 06: 1113-1121.
• 11 Borchiellini A, Fijnvandraat K, ten Cate JW. et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 1996; 88: 2951-2958.
• 12 Hulstein JJ, de Groot PG, Silence K. et al. A novel nanobody that detects the gain-offunction phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 2005; 106: 3035-3042.
• 13 Lankhof H, Damas C, Schiphorst ME. et al. Functional studies on platelet adhesion with recombinant von Willebrand Factor Type 2B mutants R543Q and R543W under conditions of flow. Blood 1997; 89: 2766-2772.
• 14 Wartiovaara-Kautto U, Joutsi-Korhonen L, Ilveskero S. et al. Platelets significantly modify procoagulant activities in haemophilia A. Haemophilia 2011; 17: 743-751.
• 15 Hoffman M, Monroe DM. Low intensity laser therapy speeds wound healing in haemophilia by enhancing platelet procoagulant activity. Wound Repair Regen 2012; 20: 770-777.
• 16 Teyssandier M, Delignat S, Rayes J. et al. Activation state of platelet in experimental severe haemophilia A. Haematolgica 2012; 97: 1115-1116.